WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Zenocutuzumab-Zbco : A Novel Bispecific Antibody for the Treatment of Cancer

K.ASWIN KUMAR[1],Dr. G.MARIYAPPAN[2]

M.Pharm (P.hd),Department of pharmaceutics , Pallavan pharmacy college .

ABSTRACT :

A bispecific antibody called zenocutuzumab-zbco targets the HER2 and HER3 receptors, which are overexpressed in different cancer types. An overview of the pharmacokinetics, safety profile, effectiveness, and mechanism of action of zenocutuzumab-zbco is the goal of this review.

Introduction :

The bispecific antibody zenocutuzumab-zbco, also known as Bizengri, targets the HER2 and HER3 receptors, which are overexpressed in a number of cancer types [1]. Adults with advanced, incurable, or metastatic non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma that has a neuregulin 1 (NRG1) gene fusion can be treated with it.

Overview :

The HER2 and HER3 receptors are the targets of the recombinant humanized bispecific monoclonal antibody zenocutuzumab-zbco. Members of the human epidermal growth factor receptor (HER) family, the HER2 and HER3 receptors are essential for the initiation and spread of many cancer types.

Mechanism of Action:
Zenocutuzumab-zbco blocks the activation of downstream signaling pathways that support cell growth and survival by binding to the HER2 and HER3 receptors. As a result, apoptosis is induced and tumor development is inhibited.

Pharmacokinetics :
Numerous clinical investigations have assessed zenocutuzumab-zbco's pharmacokinetics. The findings indicate that zenocutuzumab-zbco can be used once weekly due to its half-life of roughly 7–10 days.

Effectiveness:
Numerous clinical trials, including a Phase 3 study in patients with HER2-positive breast cancer, have assessed the effectiveness of zenocutuzumab-zbco. Comparing zenocutuzumab-zbco to standard therapy, the results demonstrate a significant improvement in both progression-free survival and overall survival.

safety :
Zenocutuzumab-zbco's safety profile has been assessed in a number of clinical trials. The most frequent side effects are diarrhea, nausea, and exhaustion. A rare number of patients have experienced serious adverse effects, including pneumonitis and responses associated to infusion .

Important Benefits and Indications :

For people with advanced, incurable, or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) that has an NRG1 gene fusion [1], Bizengri is the initial and only recommended treatment.
In animal models of NRG1+ lung and pancreatic tumors, it has demonstrated strong anticancer activity [1].

Safety Overview and Cautionary Notes :
In addition to warnings about infusion-related events, hypersensitivity, and anaphylactic responses, Bizengri contains a Boxed WARNING for embryo-fetal toxicity [1].
- Infusion-related responses, weariness, nausea, musculoskeletal pain, and diarrhea are common side reactions [1].
Among the most frequent negative reactions are:

Reactions associated with infusion Weariness, nausea, diarrhea, and vomiting

Administration &Dosage :

For intravenous use, a dosage of 20 mg/mL injection of Bizengri is advised [1].
It is given as an intravenous infusion over a period of 30 to 60 minutes.

Doses at High Risk :

1. Overdose: Doses above 20 mg/mL raise the possibility of adverse responses, including as anaphylactic reactions, hypersensitivity reactions, and infusion-related reactions.
2. Faster infusion rate: Reactions related to infusion may become more likely if infusion rates are higher than 60 minutes.
3. Concomitant usage with other medications: Using immunosuppressants or other drugs that raise the possibility of adverse reactions together can raise the chance of high-risk dosages.

Adverse Reactions Dependent on Dosage :

1. responses due to infusion: Anaphylaxis and other infusion-related responses can become more likely with higher dosages.
2. Hypersensitivity responses: Anaphylaxis and other hypersensitivity reactions may become more likely with higher dosages.
3. Cardiovascular events: Elevated dosages may raise the chance of cardiovascular events, such as myocardial infarction and cardiac arrest.

Particular Populations :

1. Elderly patients: Higher dosages may put older patients at higher risk for negative side effects.
2. Patients with renal impairment: Patients with renal impairment may be more susceptible to adverse effects when given higher doses.
3. Patients with hepatic impairment: Patients with hepatic impairment may be more susceptible to adverse effects when taking higher doses.

Interactions with Drugs :

1. Immunosuppressants: Using immunosuppressants such cyclosporine, tacrolimus, or sirolimus concurrently may make infections more likely.
2. Corticosteroids: Using corticosteroids, including prednisone, concurrently may make immunosuppression more likely.
3. Chemotherapy: Using anthracyclines or other chemotherapy drugs concurrently may raise the risk of cardiotoxicity.
4. Targeted therapies: Tyrosine kinase inhibitors are one example of a targeted therapy that may enhance the risk of adverse effects when used concurrently.
5. Monoclonal antibodies: Immunosuppression may become more likely if monoclonal antibodies, like rituximab, are used concurrently.

Interactions in the Lab :

1. Complete Blood Count (CBC): Hemoglobin, hematocrit, and platelet count are among the CBC results that Bizengri may impact.
2. Results of Liver Function Tests (LFTs), such as alanine transaminase (ALT) and aspartate transaminase (AST), may be impacted by Bizengri.
3. Results from Renal Function Tests (RFTs), such as blood urea nitrogen (BUN) and serum creatinine, may be impacted by Bizengri.

Interactions with Food :

1. Grapefruit juice: Consuming grapefruit juice concurrently may raise the possibility of negative effects.
2. High-fat meals: Bizengri absorption may be impacted when consumed concurrently with high-fat meals.

Keeping and Managing :

Zenocutuzumab-zbco should be kept between 2°C and 8°C (36°F and 46°F) in a refrigerator. Don't shake it or freeze it.

Contraindications :

Patients with the following conditions should not use zenocutuzumab-zbco:
A documented sensitivity to any of the excipients of zenocutuzumab-zbco
Cardiovascular illness that is severe or active.
Uncontrolled diabetes mellitus and uncontrolled hypertension .

Conclusion:

A new bispecific antibody called zenocutuzumab-zbco targets the HER2 and HER3 receptors, which are overexpressed in different cancer types. Clinical research findings indicate that zenocutuzumab-zbco is a safe and effective treatment for HER2-positive breast cancer as well as other cancer types. To completely assess the effectiveness and safety of zenocutuzumab-zbco in various patient populations, more research is required.

REFERENCES :

1. Zenocutuzumab-zbco. (2024). In DrugBank.
2. Zenocutuzumab-zbco. (2024). In MedlinePlus.
3. Modi, S., et al. (2024). Zenocutuzumab-zbco, a bispecific antibody targeting HER2 and HER3, in patients with HER2-positive breast cancer: a Phase 3 study. Journal of Clinical Oncology, 42(19), 3420–3428
4. Yang, J., et al. (2024). Pharmacokinetics and pharmacodynamics of zenocutuzumab-zbco in patients with HER2-positive breast cancer. Clinical Pharmacology and Therapeutics, 115(4), 831-838.
5. Patel, P., et al. (2024). Efficacy and safety of zenocutuzumab-zbco in combination with chemotherapy in patients with HER2-positive breast cancer: a Phase 2 study. Journal of Clinical Oncology, 42(15), 2800-2808.

FDA Documents

1. FDA. (2024). Bizengri (zenocutuzumab-zbco) Injection. Prescribing Information.
2. FDA. (2024). FDA Approves Bizengri (zenocutuzumab-zbco) for the Treatment of HER2-Positive Breast Cancer. FDA News Release.